Medical Innovation Prize Act of 2005
Latest action · Mar 2, 2005 Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJan 26, 2005
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Medical Innovation Prize Act of 2005 - Prohibits any person from having the right to exclusively manufacture, distribute, sell, or use a drug, a biological product, or a manufacturing process for a drug or biological product in interstate commerce, notwithstanding current Federal laws providing otherwise, including laws governing patent rights or exclusive marketing periods.
Establishes the Fund for Medical Innovation Prizes. Requires the Board of Trustees for the Fund to award prize payments for medical innovations relating to a drug, biological product, or manufacturing process for a drug or biological product. Requires an eligible award recipient to be either the first person to receive market clearance or the holder of the patent. Directs the Board to consider: (1) the number of patients who benefited from the drug, including non-U.S. patients; (2) the incremental therapeutic benefit of the drug to treat the same disease or condition; (3) the degree to which the drug addresses priority health care needs, such as global infectious diseases and neglected diseases that primarily afflict the poor in developing countries; and (4) the improved efficiency of manufacturing processes for drugs or biological processes. Allows the Board to award prize payments for no more than ten years. Allocates certain minimum payments from the Fund for priority research and development.
Requires the Comptroller General to conduct an audit to determine the Board's effectiveness in bringing to market new drugs, vaccines, biological products, and manufacturing processes in a cost-effective manner and addressing society's global medical needs.
Cosponsors
Members who signed on, in the order they did.
Committees 2
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Jan 26, 2005 |
| Health Subcommittee | Referred Feb 25, 2005 | |
| House | Judiciary Committee | Referred Jan 26, 2005 |
| Courts, Intellectual Property, Artificial Intelligence, and the Internet Subcommittee | Referred Mar 3, 2005 |
Actions 6
Everything that happened, newest first.
- Mar 2, 2005Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.
- Feb 25, 2005Referred to the Subcommittee on Health.
- Feb 2, 2005Sponsor introductory remarks on measure. (CR E149)
- Jan 26, 2005Introduced in House
- Jan 26, 2005Sponsor introductory remarks on measure. (CR E130-131)
In the Congressional Record 1
Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.
| Where | In the Record | Members | Date |
|---|---|---|---|
| Extensions | Debate and remarks E149 | Bernard Sanders I-VT | Feb 2, 2005 |
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Printed hearings 1
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
| Number | Hearing | Committee | Held |
|---|---|---|---|
| S. Hrg. 109-157 | CONVEYANCE OF LAND IN NEVADA; CONVEY LAND IN THE BEAVERHEAD-DEERLODGE FOREST, MT; EXCHANGE LAND IN IDAHO; FORT STANTON-SNOWY RIVER NATIONAL CAVE CONSERVATION AREA; AMEND THE PUBLIC LANDS CORPS ACT OF 1993; AND REVOKE LANDS IN CIBOLA NATIONAL WILDLIFE REFUGE, CA40 pages | Energy and Natural Resources Committee | Jul 20, 2005 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To provide incentives for investment in research and development for new medicines, to enhance access to new medicines, and for other purposes.
- Short Titles as Introduced
- Medical Innovation Prize Act of 2005
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Advice and consent of the Senate
- AIDS (Disease)
- Antibiotics
- Armed Forces and National Security
- Awards, medals, prizes
- Biological warfare
- Citizen participation
- Commemorations
- Commerce
- Commercial arbitration
- Communicable diseases
- Compensation (Law)
- Congress
- Congressional investigations
- Congressional reporting requirements
- Crime and Law Enforcement
- Developing countries
- Drug approvals
- Drug industry
- Drugs
- Economics and Public Finance
- Executive reorganization
- Federal advisory bodies
- Government Operations and Politics
- Health
- Intellectual property
- International Affairs
- Law
- Medical innovations
- Orphan drugs
- Patents
- Pharmaceutical research
- Presidential appointments
- Research and development
- Revolving funds
- Science, Technology, Communications
- Terrorism
- Trusts and trustees
- Vaccines
- Valuation
- World health
Text 1
Each version as it was printed, newest first.
- Jan 26, 2005Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.